Literature DB >> 2310699

Antithrombin III and procoagulant activity: sex differences and effects of the menopause.

T W Meade1, S Dyer, D J Howarth, J D Imeson, Y Stirling.   

Abstract

Among participants in the Northwick Park Heart Study, antithrombin III activity was lower in pre-menopausal women than in men of the same age. In the women, however, the menopause was associated with a significant increase in antithrombin III, mean levels in these older women then exceeding levels in men of the same age. The occurrence of the menopause was also accompanied by large increases in factor VII coagulant activity, VIIc, and in plasma fibrinogen, these increases being greater in those experiencing a natural menopause than in those whose menopause was artificial. Sex differences in antithrombin III may form part of the explanation for the observed differences between men and women in their experience of ischaemic heart disease (IHD) and also for the contrasting effects of oral contraceptives and of hormone replacement therapy on the risk of thromboembolic disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2310699     DOI: 10.1111/j.1365-2141.1990.tb02541.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  10 in total

1.  Antithrombin III Utilization in a Large Teaching Hospital.

Authors:  Cristina M Salas; Marta A Miyares
Journal:  P T       Date:  2013-12

Review 2.  Antithrombin in the treatment of burn trauma.

Authors:  Areta Kowal-Vern; Bruce A Orkin
Journal:  World J Crit Care Med       Date:  2016-02-04

3.  Hemostatic Factors and Ischemic Heart Disease Risk Among Postmenopausal Women.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

4.  Influence of Contraceptive Pill Use, Premenopause and Postmenopausal State on Hemostatic Parameters in Ethnic Chinese Women.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1996       Impact factor: 2.300

Review 5.  Transdermal estradiol/norethisterone. A review of its pharmacological properties and clinical use in postmenopausal women.

Authors:  L R Wiseman; D McTavish
Journal:  Drugs Aging       Date:  1994-03       Impact factor: 3.923

6.  Longitudinal change in serum gamma-glutamyltransferase and cardiovascular disease mortality: a prospective population-based study in 76,113 Austrian adults.

Authors:  Alexander M Strasak; Cecily C Kelleher; Jochen Klenk; Larry J Brant; Elfriede Ruttmann; Kilian Rapp; Hans Concin; Günter Diem; Karl P Pfeiffer; Hanno Ulmer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-07-10       Impact factor: 8.311

Review 7.  Plasma fibrinogen and factor VII as risk factors for cardiovascular disease.

Authors:  C C Kelleher
Journal:  Eur J Epidemiol       Date:  1992-05       Impact factor: 8.082

Review 8.  Pregnancy: An Underutilized Window of Opportunity to Improve Long-term Maternal and Infant Health-An Appeal for Continuous Family Care and Interdisciplinary Communication.

Authors:  Birgit Arabin; Ahmet A Baschat
Journal:  Front Pediatr       Date:  2017-04-13       Impact factor: 3.418

Review 9.  Sex-Gender Variable: Methodological Recommendations for Increasing Scientific Value of Clinical Studies.

Authors:  Flavia Franconi; Ilaria Campesi; Delia Colombo; Paola Antonini
Journal:  Cells       Date:  2019-05-17       Impact factor: 6.600

10.  Rivaroxaban for the treatment of venous thromboembolism in patients with nephrotic syndrome and low AT-III: A pilot study.

Authors:  Lihua Zhang; Haitao Zhang; Jiong Zhang; Hong Tian; Ju Liang; Zhihong Liu
Journal:  Exp Ther Med       Date:  2017-11-08       Impact factor: 2.447

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.